Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCTXNASDAQ:LSTANASDAQ:MIRAOTCMKTS:ULUR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCTXBriacell Therap$3.11+6.1%$3.58$2.78▼$29.40$19.85M1.3570,261 shs237,580 shsLSTALisata Therapeutics$2.94+16.7%$2.49$1.87▼$4.20$21.71M120,593 shs86,535 shsMIRAMIRA Pharmaceuticals$1.21-3.2%$1.22$0.51▼$5.01$21.15M1.962.20 million shs161,426 shsULURULURU$0.00$0.10▼$0.79$5.35M-3.136,691 shsN/A7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCTXBriacell Therap+6.14%-0.32%-0.32%-21.66%-81.24%LSTALisata Therapeutics+16.67%+17.41%+10.11%+25.11%-13.78%MIRAMIRA Pharmaceuticals-3.20%-1.63%-3.97%+14.15%+71.63%ULURULURU0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCTXBriacell Therap1.6119 of 5 stars3.52.00.00.01.10.00.6LSTALisata Therapeutics2.7359 of 5 stars3.53.00.00.02.90.01.3MIRAMIRA Pharmaceuticals2.9861 of 5 stars3.75.00.00.02.60.00.6ULURULURUN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCTXBriacell Therap 3.00Buy$32.00928.94% UpsideLSTALisata Therapeutics 3.00Buy$15.00410.20% UpsideMIRAMIRA Pharmaceuticals 3.33Buy$14.001,057.02% UpsideULURULURU 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ULUR, LSTA, BCTX, and MIRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/22/2025BCTXBriacell TherapHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.00(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCTXBriacell TherapN/AN/AN/AN/A$1.76 per shareN/ALSTALisata Therapeutics$1M25.34N/AN/A$3.49 per share0.84MIRAMIRA PharmaceuticalsN/AN/AN/AN/A$0.13 per shareN/AULURULURUN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCTXBriacell Therap-$4.79M-$8.32N/AN/AN/AN/A-479.97%-182.26%N/ALSTALisata Therapeutics-$19.99M-$2.30N/AN/AN/AN/A-61.37%-53.35%8/11/2025 (Estimated)MIRAMIRA Pharmaceuticals-$7.85M-$0.51N/AN/AN/AN/A-341.08%-272.93%8/12/2025 (Estimated)ULURULURUN/AN/A0.00N/AN/AN/AN/AN/AN/ALatest ULUR, LSTA, BCTX, and MIRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/13/2025Q3 2025BCTXBriacell Therap-$1.76-$1.64+$0.12-$1.64N/AN/A5/14/2025Q1 2025MIRAMIRA Pharmaceuticals-$0.15-$0.11+$0.04-$0.11N/AN/A5/8/2025Q1 2025LSTALisata Therapeutics-$0.53-$0.55-$0.02-$0.55N/AN/A3/28/2025Q4 2024MIRAMIRA Pharmaceuticals-$0.29-$0.15+$0.14-$0.15N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCTXBriacell TherapN/AN/AN/AN/AN/ALSTALisata TherapeuticsN/AN/AN/AN/AN/AMIRAMIRA PharmaceuticalsN/AN/AN/AN/AN/AULURULURUN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCTXBriacell TherapN/A3.413.41LSTALisata TherapeuticsN/A7.527.52MIRAMIRA PharmaceuticalsN/A12.8612.86ULURULURUN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCTXBriacell Therap15.42%LSTALisata Therapeutics8.94%MIRAMIRA Pharmaceuticals35.16%ULURULURUN/AInsider OwnershipCompanyInsider OwnershipBCTXBriacell Therap5.73%LSTALisata Therapeutics9.60%MIRAMIRA Pharmaceuticals6.65%ULURULURU1.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCTXBriacell Therap86.78 million6.39 millionOptionableLSTALisata Therapeutics308.62 million7.79 millionNot OptionableMIRAMIRA Pharmaceuticals216.92 million15.80 millionNot OptionableULURULURU230.57 million30.24 millionNot OptionableULUR, LSTA, BCTX, and MIRA HeadlinesRecent News About These CompaniesCLP-Backed Eco Walk Enhances Central Australia Experience3 hours ago | miragenews.comMVirgin Australia sale offers deals on flights in and out of the TerritoryJune 23, 2025 | ntnews.com.auNLocal 10’s Eco Hero winner’s adventures continue in the Australian OutbackJune 23, 2025 | local10.comLShadows falling across the landJune 21, 2025 | thewest.com.auTUluru with friendsJune 21, 2025 | thewest.com.auTWinter getaways in Queensland: from Brisbane to Cairns and the Great Barrier Reef plus UluruJune 20, 2025 | theaustralian.com.auJess Mauboy always wanted to be a mum. She didn't expect the way it changed her.June 20, 2025 | msn.comUluru Statement from the Heart: All Aboriginal people need access to education, employment and a safe living environmentsJune 17, 2025 | dailytelegraph.com.auDUluru Australia (Mala Walk) Walking TourJune 16, 2025 | msn.comTake That! How to sell Australia’s Northern TerritoryJune 12, 2025 | ttgmedia.comT10 BEST Places to Visit in Australia in 2024 🇦🇺 | Full Travel Guide by Lloyd & MandyJune 11, 2025 | msn.comDefining Moments in Australian History: Azaria Chamberlain final inquestJune 11, 2025 | australiangeographic.com.auAHelicopter crashes near Uluru with four people on board; two critical, other passengers stableJune 7, 2025 | ntnews.com.auNVirgin Australia launches short Uluru saleJune 4, 2025 | impactpub.com.auIVirgin Australia is slinging $99 flights from Melbourne to UluruJune 2, 2025 | timeout.comTRed-hot deal alert: Virgin Australia has just dropped $99 flights to UluruJune 1, 2025 | timeout.comTVirgin’s latest sale slashes prices on flights to Uluru, but only for a limited timeJune 1, 2025 | ntnews.com.auNVirgin launches 72-hour sale to Uluru, from just $99 one-wayJune 1, 2025 | travelweekly.com.auTVirgin drops big sale on flights to UluruJune 1, 2025 | dailytelegraph.com.auDFirst Nations leaders hope Labor will use big majority to pursue national truth tellingMay 30, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeULUR, LSTA, BCTX, and MIRA Company DescriptionsBriacell Therap NASDAQ:BCTX$3.11 +0.18 (+6.14%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$2.96 -0.15 (-4.66%) As of 06/26/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.Lisata Therapeutics NASDAQ:LSTA$2.94 +0.42 (+16.67%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$2.94 0.00 (0.00%) As of 06/26/2025 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.MIRA Pharmaceuticals NASDAQ:MIRA$1.21 -0.04 (-3.20%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$1.20 0.00 (-0.41%) As of 06/26/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.ULURU OTCMKTS:ULURULURU Inc., a specialty medical technology company, researches, develops, and commercializes a range of wound care and muco-adhesive film products based on its patented Nanoflex and OraDisc technologies in the United States and internationally. The company provides Altrazeal, a transforming powder dressing that is used for the treatment of various wounds, such as partial thickness burns, donor sites, and surgical and traumatic wounds, as well as chronic wounds, including diabetic foot, venous leg, and pressure ulcers. Its products also include Aphthasol paste for the treatment of canker sores; OraDisc A for canker sores; and OraDisc B, which is used for the treatment and management of oral pain. ULURU Inc. was founded in 1987 and is based in Addison, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside Is IBM’s AI Transformation Powering a Sustained Rally? Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst Amazon: Why Some Are Growing Bearish, and Why They’re Wrong ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside Astera Labs: AI Infrastructure Play With Significant Growth Ahead Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
